Market Place
Sourcing Support
Intellia Therapeutics Awards Inducement Grants per Nasdaq Rules
01 May 2026 //
GLOBENEWSWIRE
Intellia`s In Vivo CRISPR Therapy First To Succeed In Phase 3
27 Apr 2026 //
ENDPOINTS
Intellia Announces Proposed Public Offering Of Common Stock
27 Apr 2026 //
FIRSTWORD PHARMA
Intellia Therapeutics Reports Topline HAELO Data Apr. 27
24 Apr 2026 //
GLOBENEWSWIRE
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Rule
03 Apr 2026 //
GLOBENEWSWIRE
Intellia Therapeutics Reports Nasdaq Listing Rule 5635(c)(4)
06 Mar 2026 //
GLOBENEWSWIRE
Intellia Therapeutics Unveils Lonvo-Z Data for HAE At AAAAI 2026
03 Mar 2026 //
GLOBENEWSWIRE
FDA Fully Releases Clinical Hold On Intellia CRISPR Trials
03 Mar 2026 //
FIERCE BIOTECH
Intellia Therapeutics Joins Investor Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Intellia Therapeutics To Discuss Q4 2025 Financials & Business
19 Feb 2026 //
GLOBENEWSWIRE
Intellia Therapeutics Discloses Inducement Grants Per Nasdaq Lr
06 Feb 2026 //
GLOBENEWSWIRE
Intellia Gets FDA Nod to Resume One Gene Therapy Trial
27 Jan 2026 //
PRESS RELEASE
Intellia Therapeutics To Present At J.P. Morgan Healthcare
07 Jan 2026 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Jan 2026 //
GLOBENEWSWIRE
Intellia Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
05 Dec 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Reveals Positive Phase 1/2 Data of lonvo-z
08 Nov 2025 //
GLOBENEWSWIRE
Intellia`s CRISPR Gene Therapy Linked To Patient Fatality
07 Nov 2025 //
BIOSPACE
Intellia Therapeutics Reveals Q3 2025 Financials & Updates
06 Nov 2025 //
GLOBENEWSWIRE
FDA Puts Intellia CRISPR Trials On Hold Over Raised Liver Enzyme
30 Oct 2025 //
FIERCE BIOTECH
Intellia Therapeutics Discloses Inducement Grants Per Nasdaq LR
03 Oct 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Finishes Global Phase 3 HAELO Study
18 Sep 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Unveils Q2 2025 Financials, Highlights
07 Aug 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Grants Inducement Awards per Nasdaq Rule
07 Jul 2025 //
GLOBENEWSWIRE
Intellia Stock Sinks on Gene Therapy Patient`s Raised Enzymes
29 May 2025 //
FIERCE BIOTECH
Intellia Therapeutics Reports Inducement Grants under Nasdaq List
06 May 2025 //
GLOBENEWSWIRE
Intellia Dosed 1st Patient in Nexiguran Ziclumeran Study
03 Apr 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Reports Inducement Grants under Nasdaq List
03 Apr 2025 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Mar 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Q4 and Full-Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
Intellia To Host Q4, Full-Year 2024 Earnings Call & Updates
20 Feb 2025 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants under Nasdaq LR 5635(c)(4)
04 Feb 2025 //
GLOBENEWSWIRE
Intellia Doses Patient In HAELO Ph 3 Study Of NTLA-2002
22 Jan 2025 //
GLOBENEWSWIRE
Intellia 2025 Goals; Prioritizes NTLA-2002, Nexiguran Ziclumeran
09 Jan 2025 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
06 Jan 2025 //
GLOBENEWSWIRE
Intellia Report Inducement Grants under Nasdaq LR 5635(c)(4)
03 Dec 2024 //
GLOBENEWSWIRE
Intellia Receives FDA Designation for Nexiguran Ziclumeran in ATTR
25 Nov 2024 //
GLOBENEWSWIRE
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
18 Nov 2024 //
FIERCE BIOTECH
Intellia Announces 1st Clinical Evidence Of Nexiguran Ziclumeran
16 Nov 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Q3 2024 Results & Company Progress
07 Nov 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Two Investor Events in November
31 Oct 2024 //
GLOBENEWSWIRE
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
24 Oct 2024 //
FIERCE BIOTECH
Intellia Presents Positive Phase 2 Results For NTLA-2002 HAE
24 Oct 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces New Date for Investor Webcast
10 Oct 2024 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
Intellia Presents Phase 1 Data on nexiguran for ATTR Amyloidosis
01 Oct 2024 //
GLOBENEWSWIRE
Intellia To Present NTLA-2002 Phase 2 Data At ACAAI Annual Meeting
12 Sep 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Q2 2024 Results And Company Progress
08 Aug 2024 //
GLOBENEWSWIRE
Intellia Therapeutics To Hold Q2 2024 Earnings Call
01 Aug 2024 //
GLOBENEWSWIRE
Bioventus To Report Q2 2024 Results On August 6
30 Jul 2024 //
GLOBENEWSWIRE
Intellia Shows Re-Dosing Possible for NTLA-2001
25 Jun 2024 //
FIERCE BIOTECH
Intellia Announces Positive Data for Redosing CRISPR-Based Therapy
25 Jun 2024 //
GLOBENEWSWIRE
Intellia To Present Clinical Data On Redosed In Vivo CRISPR Therapy At PNS 2024
17 Jun 2024 //
GLOBENEWSWIRE
Intellia Announces Positive Long-Term Data from Ongoing Ph1 Study of NTLA-2002
03 Jun 2024 //
PRESS RELEASE
Intellia`s NTLA-2002 Gene Editing Shows Positive HAE Long-Term Data
02 Jun 2024 //
GLOBENEWSWIRE
Intellia Q1 2024 Earnings Call, Company Updates
02 May 2024 //
GLOBENEWSWIRE
Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
22 Mar 2024 //
ENDPTS
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 of NTLA-2001
18 Mar 2024 //
GLOBENEWSWIRE
Intellia Therapeutics to Discuss Fourth Quarter and Full-Year 2023 Earnings
14 Feb 2024 //
GLOBENEWSWIRE
Intellia Announces Publication of Positive Interim Phase 1 Data for NTLA-2002
31 Jan 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Highlights its Three-Year Strategic Priorities
04 Jan 2024 //
GLOBENEWSWIRE
